Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C

OBJECTIVES: To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) + daclatasvir (DCV); SOF + DCV + ribavirin (RBV); SOF + simeprevir (SMV). METHODS: 4...

Descripción completa

Detalles Bibliográficos
Autores principales: de Medeiros, Lucas Pereira Jorge, Lima, Mario Barreto Correa, Pires, Marcia Maria Amêndola, Maciel, Alessandra Mendonça Almeida, Medeiros, Renata Barboza Vianna, Donadel, Mariana Dermínio, Pereira, Isabela Martins Becattini, Leão, Fábio Marchon, Pires, Luiz Eduardo Amorim Correa Lima, Rzetelna, Helio, Brandão-Mello, Carlos Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korea Centers for Disease Control and Prevention 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935141/
https://www.ncbi.nlm.nih.gov/pubmed/29740528
http://dx.doi.org/10.24171/j.phrp.2018.9.2.03

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935141/
https://www.ncbi.nlm.nih.gov/pubmed/29740528
http://dx.doi.org/10.24171/j.phrp.2018.9.2.03

Ejemplares similares